Our Portfolio

Adapsyn applies proprietary algorithms and artificial intelligence to genomic and metabolomic data from microbes to find novel natural product drug candidates. The company has created a turnkey solution to drive the discovery of a diversified portfolio of drugs, thereby expediting the search for medicines that will better treat a wide spectrum of diseases.

Anaveon is a clinical-stage biopharmaceutical company, based in Switzerland, that develops biologics to modulate the function of cytokines and provide substantial therapeutic benefit to cancer patients. Our vision is to develop novel immune therapies benefiting patients suffering from a wide variety of diseases with immune pathology.

Anjarium Biosciences, strives to create and deliver solutions for patients beyond what current gene therapy platforms address today. Anjarium is developing a new generation of genetic medicines to overcome the greatest challenges facing the field, notably immunogenicity, payload capacity, individualized multiple dosing, targeted delivery and scaled manufacturing.

Aquinnah Pharmaceuticals is pursuing a novel hypothesis for the treatment of amyotrophic lateral sclerosis, Alzheimer’s disease and other neurodegenerative diseases by developing small molecule therapeutics that target persistent stress granules, a common pathology of neurodegeneration.

Arkuda has discovered new and evolving insights about the importance of progranulin and granulins in regulating lysosomal health in frontotemporal dementia and is driving the discovery of exciting new medicines for FTD-GRN and other neurodegenerative diseases.

Arrakis Therapeutics is pioneering the discovery of small-molecule medicines that directly bind and modify the biological function of RNA to treat disease. This new class of medicines, RNA-targeted small molecules (rSMs), will focus on new disease intervention points identified in the human transcriptome as well as valuable targets that are not accessible with today’s medicines.

Artios Pharma is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The company is building a pipeline of next-generation DDR programmes to target hard to treat cancers.

Autifony is a UK-based biotechnology company, spun-out from GSK in 2011. The company is focused on the development of high value, novel medicines to treat serious diseases of the central nervous system.

Autobahn is a biotechnology company developing a pipeline of transformative small molecule therapies for the treatment of CNS disorders. The company’s lead program leverages a brain-targeting chemistry platform to target the unambiguous link between thyroid hormone and myelin biology. 

BioGraph 55 is focused on developing first-in-class antibody therapies that target B-cells in T-cell inflamed solid tumors. The company’s lead program is a novel bispecific antibody that depletes regulatory B-cells to remove local immunosuppression for clinically effective anti-tumor T-cell immunity. The bispecific antibody mediates killing through a unique mode of action and is highly selective. Early efficacy data in mice supports potential monotherapy efficacy and enhanced combination efficacy with immune checkpoint inhibitors. The company uses a reverse translational approach to identify potential cellular targets within the human solid tumor microenvironment followed by translational and mouse model studies to test and validate mechanisms.

Capstan is combining the power of in vivo cell therapy with the precision of genetic medicines to develop new treatment options for patients across oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders. Our founders include inventors of the first clinically approved CAR-T and of lipid nanoparticles that are enabling mRNA medicines.

Crossbow Therapeutics, Inc., is a biotechnology company determined to improve the lives of people with cancer by unlocking the therapeutic potential of T-cell receptor (TCR)-mimetic antibodies. The company’s T-BoltTM therapies are next-generation, easily assembled immunotherapies directed with high precision at previously unreachable cancer cell targets. Crossbow’s efficient and selective approach is designed to target the entire universe of cancer proteins, dramatically expanding the potential of antibody therapy to address many types of cancer.

Curve leverage its proprietary discovery platform to identify functional microcycles that modulate targets within their native intracellular environment. The company is developing a pipeline of new small molecule drugs, initially against high priority cancer targets.

DEM Bio is pioneering the next generation of immunotherapeutics designed to unleash macrophages and other myeloid effector cells to eliminate tumors by targeting novel ‘don’t eat me’ (DEM) and ‘eat me’ (EM) signals on cancer cells and macrophages. The company’s proprietary CHoMP™ platform (Co-culture with Human Myeloid Phagocytes) explores DEM and EM signals in a systematic and unbiased manner via inter-cellular CRISPR screening using tumor cells, primary macrophages, and other innate immune effector cells. 

Enara Bio is pioneering the discovery of ‘Dark Antigens’ – a new class of cancer-specific antigens from previously uncharted genomic dark matter. The company is building a pipeline of bispecific T-cell engagers against these novel antigens to improve treatment outcomes for broad populations of cancer patients.

Enlaza’s breakthrough War-LockTM technology enables generation of unique, highly-selective biologic drugs that are engineered to become warheads with the capacity to irreversibly lock to disease related targets. This is accomplished by leveraging their novel synthetic biology platform, coupled with proprietary amino acids, to precision-engineer biological medicines with improved efficacy and safety profiles.

EvolveImmune is harnessing their “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies.  They leverage exceptional experience in immunology to swiftly advance our modular, precision biotherapeutics platform to exploit the full potential of the array of unprecedented and validated immuno-oncology targets which comprise our pipeline.

Flare Therapeutics is a biotechnology company changing the paradigm in drugging transcription factors with an initial focus in precision oncology. Flare’s proprietary engine is founded on the identification of novel druggable pockets, or ‘switch sites’, within transcription factor complexes that solve for where to drug and what to optimize for in tuning gene expression to discover small molecule precision medicines for cancer and other diseases.

FoRx Therapeutics is a recently incorporated privately held company aiming to develop first-in-class compounds for cancer treatment.  FoRx focuses on drugging key molecular targets involved in DNA replication stress, as a new approach towards the development of targeted anticancer drugs.

Grey Wolf Therapeutics is focused on inhibiting the endoplasmic reticulum aminopeptidases (ERAP1 or ERAP2), which play a key role in the antigen presentation pathway. Inhibiting ERAP1 or ERAP2 generates novel cancer antigens resulting in the mobilization of a novel T cell response against the tumor that increases tumor visibility where current therapies are ineffective, and bypasses the challenge faced once anti-tumorigenic T cells become irreversibly exhausted.

ImCheck is driving innovation in two powerful new areas of immune system modulation: the butyrophilins superfamily of immunomodulatory molecules and gamma-delta T cells.  The company is developing next generation immunotherapeutics for patients with severe unmet medical needs with a primary focus on immuno-oncology, as well as exploring opportunities in autoimmune diseases.

Immunocodex is committed to designing novel tolerogenic mRNA vaccines which re-program immune cells, re-balance the immune system, and restore health in patients suffering from autoimmune diseases. Through the integration of key tolerance-inducing signals alongside disease-specific autoantigens, we engineer effective, targeted therapies for the treatment of disease, while limiting negative systemic side effects.

ImmunOs is leading the next generation of immunotherapies by fast-tracking new discoveries of novel human immunomodulatory proteins that have a role in the innate immune system for cancer treatment.

Indendia Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as many cancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers.

Interius BioTherapeutics is an early-stage biotechnology company initially focused on treating hematologic malignancies by leveraging its platform to generate chimeric antigen receptor (CAR) T cells directly in vivo. Our unique therapeutic approach bypasses the need for ex vivo cell manipulations and the potentially toxic pre-conditioning chemotherapy required for standard CAR T-cell treatments.  The company is also developing applications beyond immuno-oncology that address diseases not amenable to current gene therapy modalities.

Kestrel Therapeutics leverages a foundation of unique science that employs a physical understanding of the drug-target interaction to build a lead program designed to potently address all RAS mutations in all tumor types.

Levicept is an asset-centric UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain.

Mediar is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis.  The platform and pipeline are based on an emerging class of novel targets – fibrotic mediators – that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs.

MindImmune Therapeutics is a preclinical stage biotech company developing first-in-class drugs that target the immune system to treat CNS diseases. The company is at the forefront of biological advances linking the peripheral immune system to neuroinflammation.

MISSION is discovering and developing first-in-class therapeutics that inhibit disease associated  deubiquitinylase enzymes (DUBs) involved in serious diseases including mitochondrial diseases, neurodegeneration, inflammation, and cancer. The company has built a proprietary world-leading DUB platform that is generating a rich pipeline of potent and selective small molecule drugs.

Montis is a biotech company targeting perivascular macrophages, a subpopulation of macrophages that interact with the endothelial cells of the vasculature. The company’s mission is to exploit these cellular interactions with therapeutics to drive and sustain immune reactions against solid tumors.

Mozart is developing CD8 Treg modulators for the treatment of autoimmune and inflammatory diseases. These molecules selectively target the regulatory CD8 T cell network to counteract early events in the autoimmune inflammatory cascade. CD8 Treg Modulators are designed to restore the intrinsic functions of regulatory CD8 T cells to suppress and eliminate pathogenic immune cells, providing durable control of autoimmune and other inflammatory diseases.

National Resilience is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely, and at scale.

Nimbus harnesses the power of computational chemistry, structural biology and AI/ML to design breakthroughs for the treatment of substantial and underserved human diseases. The company’s focus is on metabolic diseases, cancer and immune-inflammatory disorders.

Nucleome Therapeutics is decoding the disease-linked variants located in the dark matter of the human genome to discover first-in-class precision medicine. Nucleome’s platform combines pioneering 3D genome technology and machine learning to shed light on these variants by directly linking genes to diseases and mapping pathways with unprecedented precision for drug discovery for autoimmune diseases.

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glycoimmune Checkpoint inhibitors to treat cancer. The company’s proprietary platform integrates technologies and insights from Nobel laureate Carolyn Bertozzi to create a novel approach to treating cancer.

PrescriberPoint is transforming the way pharmaceutical companies interact with healthcare providers. The company is creating a digital marketplace based on a “pull” vs. “push” model where healthcare providers can access all the support they need from Pharmacos on their terms, industry-wide, in one place including access to product information, samples, rep and MSL support and patient assistance programs

ReCode is developing a proprietary non-viral Selective ORgan Targeting (SORT) LNP technology with lead indications in the rare pulmonary diseases of primary ciliary dyskinesia (PCD) and cystic fibrosis (CF). The SORT platform, which enables precise organ targeting of payloads via both systemic and local delivery, is compatible with a variety of payloads (mRNA, siRNA, DNA, small molecule), including mixed cargos such as RNA/protein complexes for gene editing.

RefleXion Medical is developing the first biologically guided radiation therapy system for treating solid tumors throughout the body. By uniquely leveraging Positron Emission Tomography (PET), RefleXion's patented technology uses signals that are continuously emitted from the tumor itself to guide the treatment beam.

Saama is an AI-driven Intelligent Clinical Cloud company, enabling the life sciences industry to conduct faster and safer clinical development and regulatory programs.  Their Life Science Analytics Cloud (LSAC) platform is used by many biopharmaceutical companies on thousands of studies.   LSAC’s rich applications facilitate an unprecedented, authoritative oversight of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring drugs to market faster. 

Storm Therapeutics is a clinical stage biotechnology company focused on discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RME) for oncology and other diseases.

Strata Oncology is a precision oncology company aiming to enable large-scale molecularly informed clinical cancer research.  The company has developed an end-to-end technology platform for sequencing tumors across a network of health systems and has used AI to build algorithms to determine the best course of therapy for patience on an individual level.

TRex Bio is a discovery-stage biotechnology company focused on making a meaningful difference in the lives of patients suffering from fatal or debilitating illnesses including autoimmune and inflammatory diseases. TRex aims to achieve this vision via functional manipulation of Tregs and other immune cells in a tissue-specific and disease-specific fashion.

Triana Biomedicines is developing molecular glue therapeutics initially tailored for targeted protein degradation applications. TRIANA is building its pipeline using a target-first, rational approach to molecular glue discovery, and aspires to develop products for a wide range of therapeutic applications.

VitaDAO is a decentralized accelerator for drug development. The core mission is the acceleration of research and development in the longevity space.

4D Molecular Therapeutics is a gene therapy company with a transformative discovery platform – Therapeutic Vector Evolution – that enables invention of optimized and proprietary AAV vectors, each specifically designed to deliver genes to specific cells and tissues in the body, allowing treatment of diseases with high unmet medical needs.

Ablexis’ AlivaMab™ Mouse technology, a world-class transgenic mouse platform, is being developed to provide the foundation for the efficient discovery and development of the next wave of human therapeutic antibodies to treat human diseases.

Accelerator New York is a leading life science investment vehicle supporting emerging biotechnology research. Accelerator will infuse strategic venture capital, entrepreneurial leadership, and critical product development capabilities into the New York City life science cluster.

AMRA is a medical technology company that analytically transforms MR images into precise body composition measurements using a cloud-based, computer aided service. These highly accurate measurements aid metabolic research and drug development in the challenging areas of obesity and its co-morbidities.

AnTolRx develops novel nanoparticle-based therapies to promote antigen-specific immune tolerance. These nanoparticles selectively target pathogenic immune cells providing a unique tolerogenic signal to induce an anti-inflammatory phenotype and better treat diseases like Type 1 Diabetes, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Multiple Sclerosis.

Aquinox is developing novel small molecule therapeutics for the treatment of cancer and inflammatory disease.

Aureon used systems pathology to develop predictive clinical tests for cancer care, as well as to enable bio-pharmaceutical research and development. 

Avid Radiopharmaceuticals, Inc. was a product-focused molecular imaging company pioneering development of radiopharmaceuticals for imaging disease pathology.

Aviir was developing cutting-edge, convenient molecular diagnostic tests to enable accurate diagnosis and prognosis of cardiovascular disease.

BioAtla develops novel monoclonal antibody and cell-based immunotherapies with improved therapeutic index for the treatment of cancer.

BioNTech leverages its deep immunology expertise and experience to develop and optimize mRNA therapeutics for serious diseases such as cancer, COVID-19, malaria and tuberculosis.

Blade Therapeutics is advancing a differentiated pipeline of oral, small-molecule therapies that include a non-competitive autotaxin inhibitor and inhibitors of dimeric calpains for the potential treatment of lung, liver and cardiac fibrosis or neurodegenerative diseases. Since the company’s founding in 2015, Blade has used a combination of in-house drug research and selective in-licensing to build a risk-diversified pipeline.

BlueLight Therapeutics was a biotechnology company that used novel structure-function-based approach to develop new therapeutic molecules against challenging drug targets to treat a wide range of serious diseases.

Bolt is a clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the innate immune system to treat cancer.

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents. Clovis intends to target development programs at specific subsets of cancer populations, and will simultaneously develop diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use.

Complexa was a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases.

Cortexyme was developing therapeutics based on a new theory of the cause of Alzheimer's and other degenerative disorders.

Cydan was an orphan drug accelerator that worked to identify and de-risk rare disease programs with therapeutic and commercial potential. 

CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody therapeutics.

DIR Technologies was a developer and provider of first-in-industry inspection solutions for the pharmaceutical packaging and manufacturing industries.

DVS Sciences Inc. was an analytical equipment and reagents development company that produced and marketed the CyTOF®, a high throughput mass cytometer for individual cell analysis based on a novel elemental mass-spectrometry detection technology, and the MAXPAR® system of novel reagents related to massively multi-parametric assays.

eFFECTOR is a clinical stage biopharmaceutical company pioneering the discovery and development of selective translation regulators as a new class of small molecule drugs for treating cancer.

Eiger is a clinical-stage biopharmaceutical company committed to developing and commercializing novel products for the treatment of Orphan diseases.

Entelos was developing computer-based disease-simulation models, called PhysioLabs that enable in-silico drug discovery and development.

Epic Sciences is focused on developing novel diagnostics to improve and personalize the treatment and management of cancer. Epic was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs).

Evolution Benefits (EB) offered innovative, integrated products for the employee benefits market.

Flexion Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA, a type of degenerative arthritis.

G-Con designs and manufactures “PODs”, portable, self-contained cGMP facility modules that offer a cost-effective and flexible alternative to large, highly capitalized pharmaceutical manufacturing facilities with fixed equipment and limited flexibility.

Genomic Health is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, they launched their first test under the brand name Oncotype DX® for early stage breast cancer.

HandyLab develops and manufactures small, low-cost nucleic acid and protein-based analysis systems based on its patented and proprietary microfluidic, miniaturized real time PCR, and nucleic acid extraction technologies. The company's lead product, Jaguar, combines rapid nucleic acid sample preparation with microfluidic PCR for nucleic acid detection. 

HD Biosciences (HDB) was a Shanghai China based clinical research organization (CRO) that provides drug discovery contract research services, with an emphasis on high value biology screening. 

Imara was developing inhibitors for sickle cell disease and other hemoglobinopathies. 

Ixchelsis Limited was a UK based biotechnology developing oxytocin receptor antagonists with the potential to treat benign prostatic hypertrophy and prostate cancer.

Jnana Therapeutics is building the first small molecule drug discovery platform dedicated to SLC transporters, an ancient membrane protein family thought to be relevant in a wide range of diseases. Jnana’s proprietary chemistry and biology platform allows the company to rapidly and comprehensively address therapeutic targets across the SLC family, with an initial focus on immuno-oncology, inflammatory disorders, and neurological diseases.

Kymera Therapeutics is pioneering a transformative new approach to treating previously untreatable diseases by advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins.  Using its protein degradation platform, the company is building a therapeutic pipeline in oncology and immunology.

Lodo used its genome-based, culture-independent platform combines DNA sequencing and bioinformatics to discover, synthesize, and characterize small-molecule therapeutics from natural microbial sources present in soil samples and the human microbiome.

M2S is a pioneer and leader in imaging and data management technology. They were the first to develop and market 3-D imaging technology to vascular surgeons. 

Mangolia Neurosciences was a drug discovery and development company focused on the creation of a novel class of neuroprotective medicines.

Mersana Therapeutics is a clinical-stage biotechnology company with highly differentiated and proprietary antibody drug conjugate (ADC) platforms that allow for significantly higher drug loads, with the potential to provide greater efficacy while simultaneously increasing tolerability.

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics.

Metabomed was a drug discovery company in the field of cancer metabolism. 

Mirna Therapeutics focused on research and development of miRNA-directed human oncology therapies.

Mitokinin is developing small molecule therapeutics targeting PINK1, a master regulator of mitochondrial quality control genetically linked to Parkinson’s disease. By selectively amplifying active-form PINK1 activity, Mitokinin is addressing cellular pathologies underlying Parkinson’s disease and ultimately slow or halt the progression of the disease.

Morphic Therapeutic is engaged in the discovery and development of a new generation of oral integrin drugs.

NeuMoDx is developing a next generation testing platform for the in vitro molecular diagnostic (MDx) market.

Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses.

NexImmune is developing novel immune-therapeutics for a variety of cancers and other diseases based on the proprietary Artificial IMmune (AIMTM) technology.

NextCure is discovering and developing first-in-class immunotherapy-based biologics for cancer and other diseases, building upon the work of its scientific founder, Dr. Lieping Chen.

Nodality, Inc. is an emerging biotechnology company focused on patient-specific classification of disease. Nodality’s technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry.  The technology can address many aspects of drug development with a primary focus on acute myeloblastic leukemia (AML) and chronic lymphocytic leukemia (CLL).

Therapeutic oncology device that delivers Tumor Treating Fields (TTFields) to tumor sites through the skin. The TTfields are low intensity, alternating electric fields that cause physical disruption of dividing (cancerous) cells, but leave normal cells largely unaffected.

Petra Pharma was developing novel small molecules for the treatment of cancer and metabolic diseases to target these cellular processes to therapeutically impact human health.

Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers.

Quartet is an early-stage biopharmaceutical company developing drugs against a novel pain target, Tetrahydrobiopterin (BH4), an essential co-factor in the production of certain neurotransmitters.

RaNA was developing a new class of therapeutics made of messenger RNA (mRNA), designed to enable in vivo production of intracellular, membrane-associated and secreted proteins.

Rhythm is a biopharmaceutical company developing peptide therapeutics that address unmet needs in metabolic diseases.

Second Genome has built a novel microbiome technology platform, resulting in a pipeline of drug discovery programs, including several microbiome-derived proteins, peptides and metabolites, with applications across gastrointestinal disease, immuno-oncology, inflammation and metabolic diseases. 

Simcha Therapeutics is an early-stage biopharmaceutical company with a focus on developing next generation cytokine immunotherapies to trigger the immune system to fight disease, particularly cancers.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that applies a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from severe rare diseases and cancer. The company launched in 2017 with a portfolio of clinically validated therapies in-licensed from Pfizer.

superDimension has developed the inReach™ system in answer to one of the most critical needs in the field of pulmonology: minimally invasive access to peripheral lung locations.

Provider of pharmaceutical supply chain security solutions to pharmaceutical companies and their trading partners seeking to enhance product integrity and supply chain efficiency.

System1 employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases for which current discovery techniques have proved least successful.

TetraLogic was a biopharmaceutical company developing novel, targeted drugs to treat cancer.

Therachon was a clinical-stage global biotechnology company focused on developing medicines for rare diseases with significant unmet need.

Triplet Therapeutics was a biotechnology company harnessing human genetics to develop treatments for repeat expansion disorders at their source.

VectivBio is a spin out of Therachon (acquired by Pfizer in 2019), that will focus on conditions caused by well understood molecular alterations that can be targeted with transformational therapeutics.   The company was acquired in 2023 by Ironwood Pharmaceuticals.

Vtesse, Inc. was a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved.

Yumanity Therapeutics was a therapeutics company focused on Parkinson’s disease, Alzheimer’s disease and ALS.

Ziarco is a clinical stage biotechnology company developing innovative therapeutics targeting inflammatory skin diseases.